| Literature DB >> 22363426 |
Kamala Thriemer1, Benedikt Ley, Shaali Ame, Lorenz von Seidlein, Gi Deok Pak, Na Yoon Chang, Ramadhan Hashim, Wolfgang Hellmut Schmied, Clara Jana-Lui Busch, Shanette Nixon, Anne Morrissey, Mahesh K Puri, Mohammad Ali, R Leon Ochiai, Thomas Wierzba, Mohammad S Jiddawi, John D Clemens, Said M Ali, Jaqueline L Deen.
Abstract
BACKGROUND: We conducted a surveillance study to determine the leading causes of bloodstream infection in febrile patients seeking treatment at three district hospitals in Pemba Island, Zanzibar, Tanzania, an area with low malaria transmission.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22363426 PMCID: PMC3281825 DOI: 10.1371/journal.pone.0030350
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Study site.
Figure 2Assembly of patients in the study.
Number (%) of bacteremia cases by participating hospital during the entire study period (2009–2010).
| Chake Chake | Mkoani | Wete | Total | p | |
| n (%) | n (%) | n (%) | n (%) | ||
| Patients enrolled | 975 | 682 | 552 | 2209 | |
| Period of surveillance | 16/03/2009–30/12/2010 | 04/05/2009–30/12/2010 | 05/08/2009–30/12/2010 | ||
| Pathogenic bacteria isolated | 30 (3.1%) | 37 (5.4%) | 12 (2.2%) | 79 (3.6%) | 0.005 |
|
| 20 | 21 | 5 | 46 | 0.3 |
| (66.7%) | (56.8%) | (41.7%) | (58.2%) | ||
|
| 2 | 5 | 5 | 12 | 0.02 |
| (6.7%) | (13.1%) | (41.7%) | (15.2%) | ||
|
| 4 | 1 | 0 | 5 | 0.17 |
| (13.3%) | (2.7%) | (0%) | (6.3%) | ||
|
| 3 | 1 | 1 | 5 | 0.36 |
| (10%) | (2.7%) | (8.3%) | (6.3%) | ||
| Hib | 1 | 2 | 0 | 3 | 1.0 |
| (3.3%) | (5.4%) | (0%) | (3.8%) | ||
| Others | 0 | 7 | 1 | 8 | 0.03 |
| (0%) | (28.9%) | (8.3%) | (10.1%) |
Age-specific ranking of pathogens during the entire study period.
| ≤5 y(n = 637) | Rank | >5 y–15 y (n = 490) | Rank | >15 y (n = 1082 | Rank | Total no (%) | Overall rank | |
| All pathogenic bacteria | 29 | 16 | 34 | 79 | ||||
| - | 10 | 1 | 12 | 1 | 24 | 1 | 46 | 1 |
| (34.5%) | (75%) | (70.6%) | (58.2%) | |||||
| - | 8 | 2 | 3 | 2 | 1 | 4 | 12 | 2 |
| (27.6%) | (18.7%) | (2.9%) | (15.2%) | |||||
| - | 0 | 0 | 5 | 2 | 5 | 3 | ||
| (0%) | (0%) | (14.7%) | (6.3%) | |||||
| - | 2 | 3 | 1 | 3 | 2 | 3 | 5 | 3 |
| (6.9%) | (6.2%) | (5.9%) | (6.3%) | |||||
| - Hib | 2 | 3 | 0 | 1 | 4 | 3 | 4 | |
| (6.9%) | (0%) | (2.9%) | (3.8%) | |||||
| - other | 7 | 0 | 1 | 8 | – | |||
| (24.1%) | (0%) | (2.9%) | (10.1%) | |||||
| Contaminants | 52 | 5 | 30 | 87 | ||||
| Total | 81 | 21 | 64 | 166 |
Crude and adjusted incidence rates for bacteremia.
| No. of cases (2010) | Population in catchment area 2010 | Crude incidence rate per 100,000 (95%CI) | p | Health seeking behaviour (%) | Adjusted rate I | Did not proceed to study nurse (%) | Adjusted rate II | No consent; insuff. blood (%) | Adjusted rate III | Blood culture sensitivity (%) | Adjusted incidencerate per 100,000(95% CI) | |
|
| 31 | 500600 | 6 (4 to 9) | 10.6 | 58 | 26.4 | 79 | 2.42 | 81 | 50 | 163(152 to 174) | |
|
| 7 | 127848 | 5 (3 to 11) | 10.6 | 52 | 26.4 | 70 | 4.01 | 73 | 50 | 146(127 to 169) | |
|
| 8 | 128917 | 6 (3 to 12) | 0.923 | 10.6 | 59 | 26.4 | 80 | 1.85 | 81 | 50 | 162(142 to 186) |
|
| 16 | 243835 | 7 (4 to 11) | 10.6 | 62 | 26.4 | 84 | 1.50 | 85 | 50 | 171(155 to 188) | |
|
| 21 | 500600 | 4 (3 to 6) | 10.6 | 40 | 26.4 | 54 | 2.42 | 55 | 50 | 110(102 to 120) | |
|
| 4 | 127848 | 3 (1 to 8) | 10.6 | 30 | 26.4 | 40 | 4.01 | 42 | 50 | 84(69 to 101) | |
|
| 5 | 128917 | 4 (2 to 9) | 0.710 | 10.6 | 37 | 26.4 | 50 | 1.85 | 51 | 50 | 101(86 to 121) |
|
| 12 | 243835 | 5 (3 to 9) | 10.6 | 46 | 26.4 | 63 | 1.50 | 64 | 50 | 128(115 to 143) | |
|
| 4 | 500600 | 1 (0.3 to 2) | 10.6 | 8 | 26.4 | 10 | 2.42 | 11 | 50 | 21(17 to 25) | |
|
| 2 | 127848 | 2 (0.4 to 6) | 10.6 | 15 | 26.4 | 20 | 4.01 | 21 | 50 | 42(32 to 54) | |
|
| 2 | 128917 | 2 (0.4 to 6) | 0.150 | 10.6 | 15 | 26.4 | 20 | 1.85 | 20 | 50 | 41(31 to 53) |
|
| 0 | 243835 | 0 (0 to 2) | 10.6 | 0 | 26.4 | 0 | 1.50 | 0 | 50 | 0(0 to 2) | |
|
| 3 | 500600 | 1 (0.2 to 2) | 10.6 | 6 | 26.4 | 8 | 2.42 | 8 | 50 | 16(13 to 20) | |
|
| 2 | 500600 | 0 | 10.6 | 4 | 26.4 | 5 | 2.42 | 5 | 50 | 11(8 to 14) |
According to projections of the national census 2002;
People attending Chake Chake Hospital by %; Kaljee and Pach, unpublished data;
According to Crump et al, 2004; Zhou & Pollard 2010, Wain et al. 2011 and 2008; Saha et al., 2010.
Crude and adjusted incidence rates for malaria.
| No. of cases in 2010 only | Population in catchment area 2010 | Crude incidence rate per 100,000 (95%CI) | p | Health-seeking behaviour (%) | Adjusted rate I | Did not proceed to study nurse (%) | Adjusted rate II | No consent;no malariatest (%) | Adjusted incidence rate per 100,000 (95%CI) | |
|
| 18 | 500600 | 4 (2 to 6) | 10.6 | 34 | 26.4 | 46 | 2.42 | 47 (42 to 54) | |
|
| 3 | 500600 | 1 (0.2 to 2) | 10.6 | 6 | 26.4 | 8 | 2.42 | 8 (6 to 11) | |
|
| 10 | 127848 | 8 (4 to 14) | 10.6 | 74 | 26.4 | 100 | 4.29 | 105 (89 to 124) | |
|
| 5 | 128917 | 4 (2 to 9) | 0.006 | 10.6 | 37 | 26.4 | 50 | 1.51 | 51 (40 to 64) |
|
| 3 | 243835 | 1 (0.4 to 4) | 10.6 | 12 | 26.4 | 16 | 1.44 | 16 (12 to 22) |
According to projections of the national census 2002;
People attending Chake Chake Hospital by %; Kaljee and Pach, unpublished data.
Susceptibility patterns of S.Typhi (n = 45)*.
| Resistant | Intermediate | Susceptible | |
| n (%) | n (%) | n (%) | |
| Ampicillin | 23 (51.1%) | 2 (4.4%) | 20 (44.4%) |
| Chloramphenicol | 22 (48.9%) | 2 (4.4%) | 21 (46.7%) |
| Trimethoprim-sulfamethoxazole (Cotrimoxazol) | 22 (48.9%) | 1 (2.2%) | 22 (48.8%) |
| Amoxicillin/Clavulanic acid | 0 (0%) | 1 (2.2%) | 44 (97.8%) |
| Cefazolin | 2 (4.4%) | 3 (6.7%) | 40 (88.9%) |
| Ceftazidime | 3 (6.7%) | 0 (0%) | 42 (93.3%) |
| Ceftriaxon | 0 (0%) | 0 (0%) | 45 (100%) |
| Ciprofloxacin | 1 (2.2%) | 0 (0%) | 44 (97.8%) |
| Gentamycin | 3 (6.7%) | 1 (2.2%) | 41 (92.1%) |
| Nalidixic acid | 14 (31.1%) | 2 (4.4%) | 29 (64.4%) |
| Ampicillin + Chloramphenicol + Trimethoprim-sulfamethoxazole | 19 (42.2%) | 0 (0%) | 19 (42.2%) |
| Ampicillin + Chloramphenicol + Trimethoprim-sulfamethoxazole + Nalidixic acid | 4 (8.9%) | 0 (0%) | 9 (20%) |
| Ampicillin + Chloramphenicol + Trimethoprim-sulfamethoxazole + Nalidixic Acid + Ciprofloxacin | 0 (0%) | 0 (0%) | 9 (20%) |
According to Performance Standards for Antimicrobial Susceptibility Testing, M100-S16, Vol 26. No. 3. CLSI, January 2007.
Susceptibility patterns of S.pneumoniae, E.coli, S.aureus and Hib*.
| Resistant | Intermediate | Susceptible | |
|
| n (%) | n (%) | n (%) |
| Chloramphenicol | 0 (0%) | 0 (0%) | 12 (100%) |
| Erythromycin | 0 (0%) | 0 (0%) | 12 (100%) |
| Trimethoprim/sulfadoxin | 7 (58.3%) | 2 (16.7%) | 3 (25%) |
| Penecillin | 3 (25%) | 0 (0%) | 9 (75%) |
According to Performance Standards for Antimicrobial Susceptibility Testing, M100-S16, Vol 26. No. 3. CLSI, January 2007.